The Treatment of Binge Eating Disorder (BED) with Lisdexamfetamine Dimesylate (LDX) in Improving Psychosocial and Occupational Functioning: With Case Study
Binge Eating Disorder (BED) is a rising health concern and has recently been recognized as an official diagnosis
under the umbrella of Eating Disorders per the Diagnostic and Statistical Manual of Mental Illnesses 5th Edition (DSM-V).
The essential feature of BED is recurrent episodes of excessive consumption of food during a discrete amount of time,
accompanied by a sense of lack of control, no compensatory behaviours, and increased level of stress. BED is associated
with many psychiatric, psychosocial, and medical comorbidities. It is because of this, that a heightened awareness must be
developed among clinicians to be able to recognize and diagnose BED. Until recently, there have not been any
pharmacological interventions available to treat patients suffering with BED. On January 30, 2015, the USFDA approved
Lisdexamfetamine Dimesylate (LDX, Vyvanse) to treat adults with mild to moderate BED. In this article, we will examine
the efficacy of using LDX in BED sufferers, and its effect on improving overall health, related quality of life, and
psychosocial functioning. Studies thus far have demonstrated LDX as being an excellent pharmacological option for
treatment of BED.
Index Terms - Binge Eating Disorder, Lisdexamfetamine, LDX